Fermenta Biotech Ltd vs Glaxosmithkline Pharmaceuticals Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 04, 2026

Key Highlights

The Latest Trading Price of Fermenta Biotech Ltd is ₹ 310 as of 04 May 10:56 . The P/E Ratio of Fermenta Biotech Ltd changed from 15.9 on March 2021 to 10.4 on March 2025 . This represents a CAGR of -8.14% over 5 yearsThe P/E Ratio of Glaxosmithkline Pharmaceuticals Ltd changed from 68.1 on March 2021 to 52.5 on March 2025 . This represents a CAGR of -5.07% over 5 years The Market Cap of Fermenta Biotech Ltd changed from ₹ 736.66 crore on March 2021 to ₹ 805.08 crore on March 2025 . This represents a CAGR of 1.79% over 5 yearsThe Market Cap of Glaxosmithkline Pharmaceuticals Ltd changed from ₹ 24401 crore on March 2021 to ₹ 48743 crore on March 2025 . This represents a CAGR of 14.84% over 5 years The revenue of Fermenta Biotech Ltd for the Dec '25 is ₹ 140.48 crore as compare to the Sep '25 revenue of ₹ 135.66 crore. This represent the growth of 3.55% The revenue of Glaxosmithkline Pharmaceuticals Ltd for the Dec '25 is ₹ 1091 crore as compare to the Sep '25 revenue of ₹ 1016 crore. This represent the growth of 7.4% The ebitda of Fermenta Biotech Ltd for the Dec '25 is ₹ 25.89 crore as compare to the Sep '25 ebitda of ₹ 32.07 crore. This represent the decline of -19.27% The ebitda of Glaxosmithkline Pharmaceuticals Ltd for the Dec '25 is ₹ 421.44 crore as compare to the Sep '25 ebitda of ₹ 371.94 crore. This represent the growth of 13.31% The net profit of Fermenta Biotech Ltd changed from ₹ -5.93 crore to ₹ 12.02 crore over 7 quarters. This represents a CAGR of NaN% The net profit of Glaxosmithkline Pharmaceuticals Ltd changed from ₹ 182.33 crore to ₹ 295.62 crore over 7 quarters. This represents a CAGR of 31.80% The Dividend Payout of Fermenta Biotech Ltd changed from 13.87 % on March 2021 to 10.78 % on March 2025 . This represents a CAGR of -4.92% over 5 yearsThe Dividend Payout of Glaxosmithkline Pharmaceuticals Ltd changed from 142.13 % on March 2021 to 99.54 % on March 2025 . This represents a CAGR of -6.88% over 5 years .

About Fermenta Biotech Ltd

Fermenta Biotech Limited was formerly incorporated as 'Duphar-Interfran Limited' in May, 1951.
The Company name was changed to 'DIL Limited' in September, 2003 and later on, was changed to 'Fermenta Biotech Limited' on October 17, 2019.
The Company is presently engaged in pharmaceuticals, manufacturing and marketing Active Pharmaceutical Ingredients, biotechnology, environmental solutions and renting of properties. Initially, Company manufactured and sold toothpaste, anti-septic lotion and pharmaceutical specialities.
It entered into collaborations with Philips-Duphar, Amsterdam (Solvay Duphar), and the Crookes Laboratories, London.
These collaborators participated in the equity capital of the Company to the extent of 25% each. In 1964, Company entered into a collaboration with Solvay Duphar to manufacture vitamin D3.

About Glaxosmithkline Pharmaceuticals Ltd

GlaxoSmithKline Pharmaceuticals Limited was erstwhile incorporated as 'Glindia Limited' in November, 1924.
The Company' s name was changed to Glaxo (India) Limited' from Glindia Limited in year 1987 and further to 'GlaxoSmithKline Pharmaceuticals Limited' from Glaxo (India) Limited effective from October 22, 2001. GlaxoSmithKline Pharmaceuticals Limited is a subsidiary of UK-based GSK Plc., a global biopharma company to unite science, technology and talent to get ahead of disease together.
The Company is headquartered in Mumbai and it has six branch offices, one manufacturing facility at Nashik in Maharashtra, 20 contract manufacturing organisations (CMOs) with regional and sales hubs across India.
The Company is engaged interalia, in the business of manufacturing, distributing and trading in pharmaceuticals.

FAQs for the comparison of Fermenta Biotech Ltd and Glaxosmithkline Pharmaceuticals Ltd

Which company has a larger market capitalization, Fermenta Biotech Ltd or Glaxosmithkline Pharmaceuticals Ltd?

Market cap of Fermenta Biotech Ltd is 916 Cr while Market cap of Glaxosmithkline Pharmaceuticals Ltd is 39,566 Cr

What are the key factors driving the stock performance of Fermenta Biotech Ltd and Glaxosmithkline Pharmaceuticals Ltd?

The stock performance of Fermenta Biotech Ltd and Glaxosmithkline Pharmaceuticals Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Fermenta Biotech Ltd and Glaxosmithkline Pharmaceuticals Ltd?

As of May 4, 2026, the Fermenta Biotech Ltd stock price is INR ₹311.4. On the other hand, Glaxosmithkline Pharmaceuticals Ltd stock price is INR ₹2335.6.

How do dividend payouts of Fermenta Biotech Ltd and Glaxosmithkline Pharmaceuticals Ltd compare?

To compare the dividend payouts of Fermenta Biotech Ltd and Glaxosmithkline Pharmaceuticals Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.